[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Thomas-Teinturier et al., 2015 - Google Patents

Ovarian reserve after treatment with alkylating agents during childhood

Thomas-Teinturier et al., 2015

View HTML
Document ID
10709650928914359646
Author
Thomas-Teinturier C
Allodji R
Svetlova E
Frey M
Oberlin O
Millischer A
Epelboin S
Decanter C
Pacquement H
Tabone M
Sudour-Bonnange H
Baruchel A
Lahlou N
De Vathaire F
Publication year
Publication venue
Human Reproduction

External Links

Snippet

STUDY QUESTION What is the effect of different alkylating agents used without pelvic radiation to treat childhood cancer in girls on the ovarian reserve in survivors? SUMMARY ANSWER Ovarian reserve seems to be particularly reduced in survivors who received …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications

Similar Documents

Publication Publication Date Title
Thomas-Teinturier et al. Ovarian reserve after treatment with alkylating agents during childhood
Lawrenz et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone
Hagen et al. Individual serum levels of anti-Müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study
Maheshwari et al. Assessment of ovarian reserve—should we perform tests of ovarian reserve routinely?
Eldar-Geva et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome
Lie Fong et al. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis
Larsen et al. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH< 10 IU/l
Weghofer et al. Live birth chances in women with extremely low-serum anti-Mullerian hormone levels
Lauritsen et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone
Esposito et al. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women
Vaidya et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding?
Al-Azemi et al. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction
Fox et al. Women’s pregnancy life history and Alzheimer’s risk: can immunoregulation explain the link?
Agacayak et al. Levels of neopterin and other inflammatory markers in obese and non-obese patients with polycystic ovary syndrome
Yamakami et al. Ovarian reserve in women with primary antiphospholipid syndrome
Peuranpää et al. Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment
Linkov et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum
Triggianese et al. Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure
Ng et al. Effect of age on ovarian stromal flow measured by three-dimensional ultrasound with power Doppler in Chinese women with proven fertility
Pirgon et al. Assessment of ovarian reserve in euthyroid adolescents with Hashimoto thyroiditis
Luisi et al. Serum anti-Müllerian hormone, inhibin B, and total inhibin levels in women with hypothalamic amenorrhea and anorexia nervosa
Wen et al. Can inhibin B reflect ovarian reserve of healthy reproductive age women effectively?
Roberts et al. Self-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivors
Köninger et al. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome
Weghofer et al. Age-specific FSH levels as a tool for appropriate patient counselling in assisted reproduction